The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.

This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat certain types of multiple sclerosis (MS) in adults. Briumvi is given as an intravenous (IV) infusion by a doctor or other ...

The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials. Briumvi ™ (ublituximab-xiiy) is now available for the treatment of relapsing forms of multiple ...

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...

Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat relapsing multiple sclerosis. This drug can interact with other medications and vaccines. For example, Briumvi can interact with ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with ...

Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every ...

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an ...